nelivaptan (BH-200) / HMNC Brain Health - LARVOL DELTA

Acute V1b vasopressin receptor antagonism ameliorates cardiovascular parameters in ovariectomized female rats subjected to chronic mild unpredictable stress. (PubMed, J Neuroendocrinol) - "Left ventricular (LV) function and aortic pulse wave velocity (aPWV) were assessed 1 h after either vehicle or nelivaptan, 10 mg/kg i.p. mean arterial pressure and heart rate were similar in gonadally intact control and CMS female rats but were significantly elevated from baseline values in CMS OVX and male rats...These findings support the concept that OVX females display cardiovascular responses similar to male rats when subjected to CMS. Systemic V1b R antagonism ameliorates aortic compliance in both male and OVX rats."

Journal • Preclinical • Cardiovascular • CNS Disorders • Depression • Psychiatry

Toward precision psychiatry: theoretical implications of bimodal response patterns to vasopressin V1b receptor inhibition in depression. (PubMed, Front Psychiatry) - P2 | "These findings support the hypothesis that nelivaptan effectively reduces depressive symptoms specifically in a subset of MDD patients, potentially identifiable by underlying HPA axis dysfunction. The confirmation of this hypothesis requires further studies integrating measures of HPA axis activity alongside response to nelivaptan treatment, facilitating precision psychiatry approaches for depression."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder (GlobeNewswire) - "HMNC Brain Health...announced today the successful completion of patient randomization for its Phase 2b OLIVE trial. The trial is investigating the efficacy and safety of BH-200, a potent vasopressin V1b receptor antagonist, alongside a predictive companion diagnostic in patients with Major Depressive Disorder (MDD)....Initial results from the OLIVE trial are expected in Q2 2025."

P2b data • Trial status • Major Depressive Disorder